Novel Assays to Address Translational Gaps in Treatment Development (UH2/UH3)

The summary for the Novel Assays to Address Translational Gaps in Treatment Development (UH2/UH3) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Novel Assays to Address Translational Gaps in Treatment Development (UH2/UH3): The overall goal of this initiative is to identify, optimize, and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders and which can be assessed in animals and humans. The goal is to support further development of these measures as assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical findings. Ultimately, the goal of this FOA is to improve the efficiency of the therapeutic development process by addressing inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.

The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of physiological measures as tools for target validation and therapeutic development. Groups will be tasked with building a target-engagement-linked-to-functional-brain-effect suite of assays with potential to translate from animals to humans and thus serve as a basis for selecting preclinical treatment candidates for further development and clinical testing. Towards this goal, the FOA will support development, optimization and evaluation of brain based assays in both preclinical species and in healthy humans and the evaluation of assay performance in response to carefully selected chemical, physiological, or behavioral manipulations.

Federal Grant Title:	Novel Assays to Address Translational Gaps in Treatment Development (UH2/UH3)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-MH-16-220
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.242
CFDA Descriptions:	Mental Health Research Grants
Current Application Deadline:	Apr 3, 2015
Original Application Deadline:	Apr 3, 2015
Posted Date:	Jan 12, 2015
Creation Date:	Jan 12, 2015
Archive Date:	May 4, 2015
Total Program Funding:	$1,500,000
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses
State governments
Native American tribal organizations (other than Federally recognized tribal governments)
Native American tribal governments (Federally recognized)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
Private institutions of higher education
County governments
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Independent school districts
Special district governments
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-16-220.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations II (U24 Clinic...; • Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations II (U01 Clinic...; • Standardizing Data and Metadata from Wearable Devices (R01 Clinical Trial Not Allowed); • NIMH Research Education Mentoring Program for HIV Researchers (R25 Clinical Trial Not Allo...; • Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IM...; • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • Urology Centers Program Interactions Core (U24 Clinical Trial Not Allowed); • Coordinating Center to Support Consortium for Neuroscience Alzheimers Disease (AD) and AD-...; • Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials o...; • Administrative Supplements to Promote Diversity in Research and Development Small Business...; • Organs-on-a-Chip in Dental, Oral, and Craniofacial Research (DOC-OoCs) (R21 Clinical Trial...